MARKET OUTLOOK

Psoriasis represents an increasingly lucrative market for biologics used to treat the moderate to severe population, for whom conventional systemic and topical treatments alone are not sufficient. TNF-alpha inhibitors and the IL-12/23 inhibitor Stelara (Janssen) continue to dominate biologics patient share, but are being challenged by the arrival of highly effective IL-17 inhibitors; notably, uptake of Novartis’ Cosentyx has been momentous since its launch, but is facing competition from the more recent Eli Lilly’s Taltz. Additionally, more than three years into its launch in the United Sates, Celgene’s Otezla is steadily gaining patient shares in early lines of therapy.

QUESTIONS ANSWERED

· What patient share do key therapies and brands garner by line of therapy in newly diagnosed psoriasis patients? What are the quarterly trends in prescribing among recently-treated and new diagnosed psoriasis patients?

· How have non-TNF-alpha inhibitor biologics and Otezla been integrated into the treatment algorithm?

· What proportion of psoriasis patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?

· What percentage of psoriasis patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?

· What are the product-level compliance and persistency rates among drug-treated patients with psoriasis?

Table of contents

  • Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)
    • Treatment-Algorithms-Claims-Data-Analysis-Psoriasi-US-PPT-March-2018

Author(s): Yingdee Unhavaithaya

Yingdee Unhavaithaya is a Business Insights Analyst on the Immune and Inflammatory Disorders team at Decision Resources Group, primarily focusing on psoriasis. Prior to joining DRG, Yingdee was an analyst at Citeline, where he analyzed data on oncology clinical trials ; He was also a business development intern at the Massachusetts General Hospital Research Ventures and Licensing office, where he performed market research to look for invention licensing ; Yingdee received his in cell biology from the University of Massachusetts Medical School, and a in biology from the University of Pittsburgh at Greensburg.


Related Reports

Psoriasis | Landscape & Forecast | Disease Landscape & Forecast

The psoriasis therapy market has become increasingly lucrative owing to the growing use of biologics. The dominance of the tumor necrosis factor (TNF)-a...

View Details

Psoriasis | Geographic Focus: China | Psoriasis|China In-Depth|China

Psoriasis is an incurable chronic skin condition known to affect more than 8 million people in China. China’s psoriasis market has grown significantly over the last few years owing to the g...

View Details

Psoriasis | Current Treatment | Detailed, Expanded Analysis Pediatric Psoriasis - Treatment Algorithms - Claims Data Analysis (US)

Psoriasis is a chronic, inflammatory autoimmune skin disease that can affect children, adolescents, and adults. Given the limited number of therapies approved for pediatric psoriasis, treatment o...

View Details

Psoriasis | Current Treatment | Detailed, Expanded Analysis Adult Psoriasis - Treatment Algorithms - Claims Data Analysis (US)

The adult psoriasis market has become increasingly lucrative owing to the growing use of biologics in the moderate to severe population, which cannot be adequately controlled with conventional sy...

View Details